Medicare's 2027 Cash Infusion: A Boon for Insurers, a Blow to Drug Access

The Centers for Medicare & Medicaid Services (CMS) has proposed a net 2.4% increase in Medicare hospital outpatient prospective payment system rates for calendar year 2027 [c6, c9]. This move is projected to inject over $13 billion into Medicare Advantage plans alone

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…

— Wall St Engine link

. However, this financial uplift for insurers and some providers comes with a significant downside: proposed cuts of nearly 40% to payments for drugs acquired under the 340B program

"CMS on Thursday proposed cutting Medicare Part B payments to 340B hospitals by nearly 40%, reviving a high-stakes clash between [...]"

. This reduction could severely impact the affordability of essential medications for vulnerable patient populations who rely on these discounts for their care

"We are deeply concerned about CMS' continued assault on the 340B drug pricing program, including its proposal to reduce 340B reimbursement rates by a shocking 33.4%."

. The dual nature of these proposals has sparked immediate reactions, with some sectors celebrating the payment increases while others voice deep concern over the potential erosion of crucial drug access programs.

The headline from CMS is a projected 2.4% net increase in Medicare hospital outpatient payment rates for 2027 [c6, c9]. This figure, described by some as a 'cash injection' for health insurers, is expected to translate into billions in additional payments for Medicare Advantage plans

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…

— Wall St Engine link

. The market responded swiftly, with major players like $UNH seeing significant gains in after-hours trading [c1, c4]. This increase is framed by CMS as a move to 'strengthen care quality and cut drug costs'

"In a move aimed at reshaping how Medicare pays for certain outpatient care services, the Centers for Medicare & Medicaid Services (CMS) today announced a proposed rule that would revise payment policies and rates for hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs) beginning in Calendar Year (CY) 2027 — signaling a renewed federal push to lower costs for Medicare beneficiaries, safeguard taxpayer investments, and strengthen access to high-quality care across the country."

, a narrative that conveniently overlooks the other half of the proposed rule. For many, this signals a favorable environment for managed care, potentially leading to expanded benefits or more aggressive marketing in the coming years.

While hospitals and insurers eye the outpatient payment increase, a starkly different reality is emerging for the 340B drug discount program. CMS is proposing to slash payments for drugs acquired under 340B by nearly 40%

"CMS on Thursday proposed cutting Medicare Part B payments to 340B hospitals by nearly 40%, reviving a high-stakes clash between [...]"

. The American Hospital Association calls this an 'assault' and highlights a proposed reduction of 33.4% specifically for 340B reimbursement rates

"We are deeply concerned about CMS' continued assault on the 340B drug pricing program, including its proposal to reduce 340B reimbursement rates by a shocking 33.4%."

. This program is critical for safety-net hospitals serving vulnerable populations, enabling them to offer discounted medications and essential services. Such a drastic cut threatens the financial viability of these institutions and, by extension, the access to affordable drugs for millions of patients who depend on them.

The immediate beneficiaries of this CMS proposal appear to be large health insurers and potentially some hospital systems that can absorb or offset the 340B cuts. Stocks like $UNH, $HUM, and $CVS are positioned to benefit from the higher Medicare Advantage reimbursement rates

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…

— Casey | Trade Tracs link

. Conversely, hospitals that heavily rely on the 340B program, particularly those serving low-income and uninsured patients, face significant financial headwinds. The 'nearly 40%' cut to 340B payments

"CMS on Thursday proposed cutting Medicare Part B payments to 340B hospitals by nearly 40%, reviving a high-stakes clash between [...]"

could force difficult choices, potentially leading to reduced services or increased out-of-pocket costs for patients who are already struggling. This disparity underscores a fundamental tension between industry profitability and patient access to care.